11:04 , Sep 5, 2018 |  BioCentury  |  Finance

Fulcrum’s genetic levers

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round. Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital,...
19:06 , Dec 22, 2016 |  BC Innovations  |  Translation in Brief

Pin the tail

Stanford University researchers have provided preclinical proof of concept that adding polyadenine (polyA) tails to atypical sites on mRNAs could treat disease. Although the team applied the strategy to the transcript of the fibrosis target,...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Company News

Evotec, Facio deal

Facio and Evotec partnered to discover small molecules to treat facioscapulohumeral dystrophy (FSHD), a muscle wasting disease. The partners will develop a high throughput assay to screen for small molecules that increase activity of structural...
07:00 , Mar 14, 2013 |  BC Innovations  |  Strategy

GSK goes deep with DPAc

GlaxoSmithKline plc's Discovery Partnerships with Academia program has struck new deals with laboratories at the Vanderbilt University School of Medicine and The Hospital for Sick Children to identify compounds for severe obesity and cystic fibrosis,...
08:00 , Jan 10, 2013 |  BC Innovations  |  Strategy

DUX4 partnership

Researchers at the Fred Hutchinson Cancer Research Center have identified a mutation that induces expression of the transcription factor double homeobox 4 and could be targeted in facioscapulohumeral muscular dystrophy.1 Based on this and previous...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

GlaxoSmithKline, Fred Hutchinson deal

GlaxoSmithKline and the research center partnered under GSK's Discovery Partnerships with Academia to develop products to treat facioscapulohumeral muscular dystrophy (FSHD). The center will receive an undisclosed upfront payment and research expenses and is eligible...